![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 20, 2022
This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
December 20, 2022
In July, the field of radiation oncology lost an expert and pioneer
December 20, 2022
In November, the field of breast cancer research lost a revolutionary
December 20, 2022
In an annual evaluation, 36 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
December 20, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
October 13, 2022
Research results in breast and kidney cancer; recognition of key colleagues; and a sneak peek of the Fall 2022 Group Meeting
August 16, 2022
President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval
August 16, 2022
June 21, 2022
Reflections on the spring conference season, including highlights from the Spring Group Meeting and ASCO's Annual Meeting
June 21, 2022
This single-arm phase 2 study aims to rid patients of residual disease following initial treatment
June 21, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019